PTEN at the interface of immune tolerance and tumor suppression
Received date: 12 Oct 2016
Accepted date: 12 Jan 2017
Published date: 19 Jun 2017
Copyright
BACKGROUND: PTEN is well known to function as a tumor suppressor that antagonizes oncogenic signaling and maintains genomic stability. ThePTEN gene is frequently deleted or mutated in human cancers and the wide cancer spectrum associated with PTEN deficiency has been recapitulated in a variety of mouse models ofPten deletion or mutation. Pten mutations are highly penetrant in causing various types of spontaneous tumors that often exhibit resistance to anticancer therapies including immunotherapy. Recent studies demonstrate that PTEN also regulates immune functionality.
OBJECTIVE: To understand the multifaceted functions of PTEN as both a tumor suppressor and an immune regulator.
METHODS: This review will summarize the emerging knowledge of PTEN function in cancer immunoediting. In addition, the mechanisms underlying functional integration of various PTEN pathways in regulating cancer evolution and tumor immunity will be highlighted.
RESULTS: Recent preclinical and clinical studies revealed the essential role of PTEN in maintaining immune homeostasis, which significantly expands the repertoire of PTEN functions. Mechanistically, aberrant PTEN signaling alters the interplay between the immune system and tumors, leading to immunosuppression and tumor escape.
CONCLUSION: Rational design of personalized anti-cancer treatment requires mechanistic understanding of diverse PTEN signaling pathways in modulation of the crosstalk between tumor and immune cells.
Key words: PTEN; phosphoinositide 3-kinase; regulatory T cells; genome; epigenome; metabolism
Andrew Brandmaier , Sheng-Qi Hou , Sandra Demaria , Silvia C. Formenti , Wen H. Shen . PTEN at the interface of immune tolerance and tumor suppression[J]. Frontiers in Biology, 2017 , 12(3) : 163 -174 . DOI: 10.1007/s11515-017-1443-5
1 |
Anzelon A N, Wu H, Rickert R C (2003). Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol, 4(3): 287–294
|
2 |
Bassi C, Ho J, Srikumar T , Dowling R J , Gorrini C , Miller S J , Mak T W , Neel B G , Raught B , Stambolic V (2013). Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science, 341(6144): 395–399
|
3 |
Biggs W H 3rd, Meisenhelder J, Hunter T, Cavenee W K , Arden K C (1999). Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA, 96(13): 7421–7426
|
4 |
Bronisz A, Godlewski J, Wallace J A , Merchant A S , Nowicki M O , Mathsyaraja H , Srinivasan R , Trimboli A J , Martin C K , Li F, Yu L, Fernandez S A , Pécot T , Rosol T J , Cory S, Hallett M, Park M , Piper M G , Marsh C B , Yee L D , Jimenez R E , Nuovo G , Lawler S E , Chiocca E A , Leone G , Ostrowski M C (2012). Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol, 14(2): 159–167
|
5 |
Brunet A, Bonni A, Zigmond M J , Lin M Z , Juo P, Hu L S, Anderson M J, Arden K C, Blenis J, Greenberg M E (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96(6): 857–868
|
6 |
Bucheit A D, Chen G, Siroy A , Tetzlaff M , Broaddus R , Milton D , Fox P, Bassett R, Hwu P , Gershenwald J E , Lazar A J , Davies M A (2014). Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res, 20(21): 5527–5536
|
7 |
Buckler J L, Walsh P T, Porrett P M, Choi Y, Turka L A (2006). Cutting edge: T cell requirement for CD28 costimulation is due to negative regulation of TCR signals by PTEN. J Immunol, 177(7): 4262–4266
|
8 |
Chen H H, Handel N, Ngeow J , Muller J , Huhn M, Yang H T, Heindl M, Berbers R M , Hegazy A N , Kionke J , Travis S , Merkenschlager A , Kiess W , Wittekind C , Walker L , Ehl S, Yehia L, Sack U , Blaser R , Rensing-Ehl A , ReifenbergerJ , KeithJ (2016). Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells. J Allergy Clin Immunol, 139(2): 607–620
|
9 |
Chen R, Kim O, Yang J , Sato K, Eisenmann K M, McCarthy J, Chen H , Qiu Y (2001). Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem, 276(34): 31858–31862
|
10 |
Chen Z, Trotman L C, Shaffer D, Lin H K , Dotan Z A , Niki M, Koutcher J A, Scher H I, Ludwig T, Gerald W , Cordon-Cardo C , Paolo Pandolfi P (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature, 436(7051): 725–730
|
11 |
Chen Z H, Zhu M, Yang J , Liang H , He J, He S, Wang P , Kang X, McNutt M A, Yin Y, Shen W H (2014). PTEN interacts with histone H1 and controls chromatin condensation. Cell Reports, 8(6): 2003–2014
|
12 |
Crellin N K, Garcia R V, Levings M K (2007). Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells. Blood, 109(5): 2014–2022
|
13 |
Dave B, Migliaccio I, Gutierrez M C , Wu M F , Chamness G C , Wong H, Narasanna A, Chakrabarty A , Hilsenbeck S G , Huang J , Rimawi M , Schiff R , Arteaga C , Osborne C K , Chang J C (2011). Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol, 29(2): 166–173
|
14 |
Delgoffe G M, Woo S R, Turnis M E, Gravano D M, Guy C, Overacre A E , Bettini M L , Vogel P , Finkelstein D , Bonnevier J , Workman C J , Vignali D A A (2013). Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature, 501(7466): 252–256
|
15 |
Di Cristofano A , Kotsi P , Peng Y F , Cordon-Cardo C , Elkon K B , Pandolfi P P (1999). Impaired Fas response and autoimmunity in Pten+/− mice. Science, 285(5436): 2122–2125
|
16 |
Di Cristofano A , Pesce B , Cordon-Cardo C , Pandolfi P P (1998). Pten is essential for embryonic development and tumour suppression. Nat Genet, 19(4): 348–355
|
17 |
Dunn G P, Bruce A T, Ikeda H, Old L J , Schreiber R D (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol, 3(11): 991–998
|
18 |
Eppihimer M J , Gunn J, Freeman G J, Greenfield E A, Chernova T, Erickson J , Leonard J P (2002). Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation, 9(2): 133–145
|
19 |
Feng J, Liang J, Li J , Li Y, Liang H, Zhao X , McNutt M A , Yin Y (2015). PTEN Controls the DNA Replication Process through MCM2 in Response to Replicative Stress. Cell Reports, 13(7): 1295–1303
|
20 |
Francisco L M , Salinas V H , Brown K E , Vanguri V K , Freeman G J , Kuchroo V K , Sharpe A H (2009). PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med, 206(13): 3015–3029
|
21 |
Galon J, Angell H K, Bedognetti D, Marincola F M (2013). The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity, 39(1): 11–26
|
22 |
Garcia-Cao I, Song M S, Hobbs R M, Laurent G, Giorgi C , de Boer V C , Anastasiou D , Ito K, Sasaki A T, Rameh L, Carracedo A , Vander Heiden M G , Cantley L C , Pinton P , Haigis M C , Pandolfi P P (2012). Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell, 149(1): 49–62
|
23 |
Gong L, Govan J M, Evans E B, Dai H, Wang E , Lee S W , Lin H K , Lazar A J , Mills G B , Lin S Y (2015). Nuclear PTEN tumor-suppressor functions through maintaining heterochromatin structure. Cell Cycle, 14(14): 2323–2332
|
24 |
Hanahan D, Weinberg R A (2011). Hallmarks of cancer: the next generation. Cell, 144(5): 646–674
|
25 |
He J, Kang X, Yin Y , Chao K S , Shen W H (2015). PTEN regulates DNA replication progression and stalled fork recovery. Nat Commun, 6: 7620
|
26 |
He J, Zhang Z, Ouyang M , Yang F, Hao H, Lamb K L , Yang J, Yin Y, Shen W H (2016). PTEN regulates EG5 to control spindle architecture and chromosome congression during mitosis. Nat Commun, 7: 12355
|
27 |
Hildebrandt M A , Yang H, Hung M C, Izzo J G, Huang M, Lin J , Ajani J A , Wu X (2009). Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol, 27(6): 857–871
|
28 |
Hsieh C S, Lee H M, Lio C W (2012). Selection of regulatory T cells in the thymus. Nat Rev Immunol, 12(3): 157–167
|
29 |
Huynh A, DuPage M, Priyadharshini B , Sage P T , Quiros J , Borges C M , Townamchai N , Gerriets V A , Rathmell J C , Sharpe A H , Bluestone J A , Turka L A (2015). Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat Immunol, 16(2): 188–196
|
30 |
Jiang H, Hegde S, Knolhoff B L , Zhu Y, Herndon J M, Meyer M A, Nywening T M, Hawkins W G, Shapiro I M, Weaver D T, Pachter J A, Wang-Gillam A, DeNardo D G (2016). Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med, 22(8): 851–860
|
31 |
Josefowicz S Z , Lu L F , Rudensky A Y (2012). Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol, 30:531–564
|
32 |
Kane L P, Andres P G, Howland K C, Abbas A K, Weiss A (2001). Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines. Nat Immunol, 2(1): 37–44160;
|
33 |
Kang X, Song C, Du X , Zhang C, Liu Y, Liang L, He J , Lamb K, Shen W H, Yin Y (2015). PTEN stabilizes TOP2A and regulates the DNA decatenation. Sci Rep, 5:17873
|
34 |
Komatsu N, Okamoto K, Sawa S , Nakashima T , Oh-hora M , Kodama T , Tanaka S , Bluestone J A , Takayanagi H (2014). Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med, 20(1): 62–68
|
35 |
Kral J B, Kuttke M, Schrottmaier W C , Birnecker B , Warszawska J , Wernig C , Paar H, Salzmann M, Sahin E , Brunner J S , Österreicher C , Knapp S , Assinger A , Schabbauer G (2016). Sustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways. Sci Rep, 6: 23034
|
36 |
Kritikou E (2007). PTEN- a new guardian of the genome. Nat Rev Mol Cell Biol, 8(3): 179
|
37 |
Lee J J, Kim B C, Park M J, Lee Y S, Kim Y N, Lee B L, Lee J S (2011). PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ, 18(4): 666–677
|
38 |
Li J, Yen C, Liaw D , Podsypanina K , Bose S, Wang S I, Puc J, Miliaresis C , Rodgers L , McCombie R , Bigner S H , Giovanella B C , Ittmann M , Tycko B , Hibshoosh H , Wigler M H , Parsons R (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 275(5308): 1943–1947
|
39 |
Li Y, Jia Y, Pichavant M , Loison F , Sarraj B , Kasorn A , You J, Robson B E, Umetsu D T, Mizgerd J P, Ye K, Luo H R (2009). Targeted deletion of tumor suppressor PTEN augments neutrophil function and enhances host defense in neutropenia-associated pneumonia. Blood, 113(20): 4930–4941
|
40 |
Loke P, Allison J P (2003). PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA, 100(9): 5336–5341
|
41 |
Maehama T, Dixon J E (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem, 273(22): 13375–13378
|
42 |
McEllin B, Camacho C V, Mukherjee B, Hahm B , Tomimatsu N , Bachoo R M , Burma S (2010). PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res, 70(13): 5457–5464
|
43 |
Mendes-Pereira A M , Martin S A , Brough R , McCarthy A , Taylor J R , Kim J S , Waldman T , Lord C J , Ashworth A (2009). Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med, 1(6–7): 315–322
|
44 |
Michalek R D, Gerriets V A, Jacobs S R, Macintyre A N, MacIver N J, Mason E F, Sullivan S A, Nichols A G, Rathmell J C (2011). Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol, 186(6): 3299–3303
|
45 |
Nardella C, Clohessy J G, Alimonti A, Pandolfi P P (2011). Pro-senescence therapy for cancer treatment. Nat Rev Cancer, 11(7): 503–511
|
46 |
Newton R, Priyadharshini B, Turka L A (2016). Immunometabolism of regulatory T cells. Nat Immunol, 17(6): 618–625
|
47 |
Ortega-Molina A, Efeyan A, Lopez-Guadamillas E, Munoz-Martin M , Gomez-Lopez G , Canamero M , Mulero F , Pastor J , Martinez S , Romanos E , Mar Gonzalez-Barroso M , Rial E, Valverde A M, Bischoff J R, Serrano M (2012). Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab, 15(3): 382–394
|
48 |
Ouyang W, Liao W, Luo C T , Yin N, Huse M, Kim M V , Peng M, Chan P, Ma Q , Mo Y, Meijer D, Zhao K , Rudensky A Y , Atwal G , Zhang M Q , Li M O (2012). Novel Foxo1-dependent transcriptional programs control T(reg) cell function. Nature, 491(7425): 554–559
|
49 |
Pan F, Yu H, Dang E V , Barbi J , Pan X, Grosso J F, Jinasena D, Sharma S M , McCadden E M , Getnet D , Drake C G , Liu J O , Ostrowski M C , Pardoll D M (2009). Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science, 325(5944): 1142–1146
|
50 |
Papa A, Wan L, Bonora M , Salmena L , Song M S , Hobbs R M , Lunardi A , Webster K , Ng C, Newton R H, Knoblauch N, Guarnerio J , Ito K, Turka L A, Beck A H, Pinton P, Bronson R T , Wei W, Pandolfi P P (2014). Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function. Cell, 157(3): 595–610
|
51 |
Parsa A T, Waldron J S, Panner A, Crane C A , Parney I F , Barry J J , Cachola K E , Murray J C , Tihan T , Jensen M C , Mischel P S , Stokoe D , Pieper R O (2007). Loss of tumor suppressor PTEN function increases B7–H1 expression and immunoresistance in glioma. Nat Med, 13(1): 84–88
|
52 |
Patsoukis N, Bardhan K, Chatterjee P , Sari D, Liu B, Bell L N , Karoly E D , Freeman G J , Petkova V , Seth P, Li L, Boussiotis V A (2015). PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun, 6: 6692
|
53 |
Patsoukis N, Li L, Sari D , Petkova V , Boussiotis V A (2013). PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol Cell Biol, 33(16): 3091–3098
|
54 |
Peng W, Chen J Q, Liu C, Malu S , Creasy C , Tetzlaff M T , Xu C, McKenzie J A, Zhang C, Liang X , Williams L J , Deng W, Chen G, Mbofung R , Lazar A J , Torres-Cabala C A , Cooper Z A , Chen P L , Tieu T N , Spranger S , Yu X, Bernatchez C, Forget M A , Haymaker C , Amaria R , McQuade J L , Glitza I C , Cascone T , Li H S , Kwong L N , Heffernan T P , Hu J, Bassett R L, Bosenberg M W, Woodman S E, Overwijk W W, Lizee G, Roszik J , Gajewski T F , Wargo J A , Gershenwald J E , Radvanyi L , Davies M A , Hwu P (2016). Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov, 6(2): 202–216
|
55 |
Podsypanina K, Ellenson L H, Nemes A, Gu J , Tamura M , Yamada K M , Cordon-Cardo C , Catoretti G , Fisher P E , Parsons R (1999). Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA, 96(4): 1563–1568
|
56 |
Riou C, Yassine-Diab B, Van grevenynghe J, Somogyi R , Greller L D , Gagnon D , Gimmig S , Wilkinson P , Shi Y, Cameron M J, Campos-Gonzalez R, Balderas R S , Kelvin D , Sekaly R P , Haddad E K (2007). Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells. J Exp Med, 204(1): 79–91
|
57 |
Schreiber R D , Old L J , Smyth M J (2011). Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science, 331(6024): 1565–1570
|
58 |
Sharma M D, Huang L, Choi J H , Lee E J , Wilson J M , Lemos H , Pan F, Blazar B R, Pardoll D M, Mellor A L, Shi H, Munn D H (2013). An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity, 38(5): 998–1012
|
59 |
Sharma M D, Shinde R, McGaha T L , Huang L , Holmgaard R B , Wolchok J D , Mautino M R , Celis E , Sharpe A H , Francisco L M , Powell J D , Yagita H , Mellor A L , Blazar B R , Munn D H (2015). The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Sci Adv, 1(10): e1500845
|
60 |
Sharma P, Allison J P (2015). The future of immune checkpoint therapy. Science, 348(6230): 56–61
|
61 |
Shen W H, Balajee A S, Wang J, Wu H , Eng C, Pandolfi P P, Yin Y (2007). Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell, 128(1): 157–170
|
62 |
Shi L Z, Wang R, Huang G , Vogel P , Neale G , Green D R , Chi H (2011). HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med, 208(7): 1367–1376
|
63 |
Shrestha S, Yang K, Guy C , Vogel P , Neale G , Chi H (2015). Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat Immunol, 16(2): 178–187
|
64 |
Song M S, Carracedo A, Salmena L , Song S J , Egia A, Malumbres M, Pandolfi P P (2011). Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell, 144(2): 187–199
|
65 |
Soond D R, Garcon F, Patton D T , Rolf J, Turner M, Scudamore C , Garden O A , Okkenhaug K (2012). Pten loss in CD4 T cells enhances their helper function but does not lead to autoimmunity or lymphoma. J Immunol, 188(12): 5935–5943
|
66 |
Stambolic V, Tsao M S, Macpherson D, Suzuki A , Chapman W B , Mak T W (2000). High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/− mice. Cancer Res, 60(13): 3605–3611
|
67 |
Steck P A, Pershouse M A, Jasser S A, Yung W K, Lin H, Ligon A H , Langford L A , Baumgard M L , Hattier T , Davis T , Frye C, Hu R, Swedlund B , Teng D H R , Tavtigian S V (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet, 15(4): 356–362
|
68 |
Subramanian K K , Jia Y, Zhu D, Simms B T , Jo H, Hattori H, You J , Mizgerd J P , Luo H R (2007). Tumor suppressor PTEN is a physiologic suppressor of chemoattractant-mediated neutrophil functions. Blood, 109(9): 4028–4037
|
69 |
Sun Z, Huang C, He J , Lamb K L , Kang X, Gu T, Shen W H , Yin Y (2014). PTEN C-terminal deletion causes genomic instability and tumor development. Cell Reports, 6(5): 844–854
|
70 |
Suzuki A, Yamaguchi M T, Ohteki T, Sasaki T , Kaisho T , Kimura Y , Yoshida R , Wakeham A , Higuchi T , Fukumoto M , Tsubata T , Ohashi P S , Koyasu S , Penninger J M , Nakano T , Mak T W (2001). T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity, 14(5): 523–534
|
71 |
Tamura M, Gu J, Matsumoto K , Aota S, Parsons R, Yamada K M (1998). Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science, 280(5369): 1614–1617
|
72 |
Teng M W, Galon J, Fridman W H , Smyth M J (2015). From mice to humans: developments in cancer immunoediting. J Clin Invest, 125(9): 3338–3346
|
73 |
Terawaki S, Chikuma S, Shibayama S , Hayashi T , Yoshida T , Okazaki T , Honjo T (2011). IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol, 186(5): 2772–2779
|
74 |
Torres J, Pulido R (2001). The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem, 276(2): 993–998
|
75 |
Toso A, Revandkar A, Di Mitri D , Guccini I , Proietti M , Sarti M , Pinton S , Zhang J , Kalathur M , Civenni G , Jarrossay D , Montani E , Marini C , Garcia-Escudero R , Scanziani E , Grassi F , Pandolfi P P , Catapano C V , Alimonti A (2014). Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Reports, 9(1): 75–89
|
76 |
Trimboli A J, Cantemir-Stone C Z, Li F, Wallace J A , Merchant A , Creasap N , Thompson J C , Caserta E , Wang H, Chong J L, Naidu S, Wei G , Sharma S M , Stephens J A , Fernandez S A , Gurcan M N , Weinstein M B , Barsky S H , Yee L, Rosol T J, Stromberg P C, Robinson M L, Pepin F, Hallett M , Park M, Ostrowski M C, Leone G (2009). Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature, 461(7267): 1084–1091
|
77 |
van Ree J H , Nam H J , Jeganathan K B , Kanakkanthara A , van Deursen J M (2016). Pten regulates spindle pole movement through Dlg1-mediated recruitment of Eg5 to centrosomes. Nat Cell Biol, 18(7): 814–821
|
78 |
Vazquez F, Ramaswamy S, Nakamura N , Sellers W R (2000). Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol, 20(14): 5010–5018
|
79 |
Vesely M D, Kershaw M H, Schreiber R D , Smyth M J (2011). Natural innate and adaptive immunity to cancer. Annu Rev Immunol, 29: 235–271
|
80 |
Wang G, Li Y, Wang P , Liang H , Cui M, Zhu M, Guo L , Su Q, Sun Y, McNutt M A , Yin Y (2015). PTEN regulates RPA1 and protects DNA replication forks. Cell Res, 25(11): 1189–1204
|
81 |
Yadav M, Louvet C, Davini D , Gardner JM , Martinez M -Llordella S, Bailey-Bucktrout B A, Anthony F M, Sverdrup R, Head D J , Kuster P , Ruminski D , Weiss D , V J A on Schack, Bluestone (2012). Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med, 209(10): 1713–1722, S1711–1719160;
|
82 |
Yin Y, Shen W H (2008). PTEN: a new guardian of the genome. Oncogene, 27(41): 5443–5453
|
83 |
Zhang Z, Hou S Q, He J, Gu T , Yin Y, Shen W H (2016). PTEN regulates PLK1 and controls chromosomal stability during cell division. Cell Cycle, 15(18): 2476–2485
|
/
〈 | 〉 |